CRISPR rating reiterated
Citizens reiterates CRISPR Therapeutics stock rating due to gene editing prospects, indicating confidence in the company's technology
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.